An Obesity Treatment Doomed for Failure?

Finding the "killer app" for treating obese individuals has seen no shortage of efforts result in failure over the years. The slow start of VIVUS' (NASDAQ: VVUS  ) Qsymia has investors doubting the market potential of both it and Arena Pharmaceuticals'  (NASDAQ: ARNA  ) new drugs targeting the problem. In the following video, health care bureau chief Brenton Flynn runs through yet another example of a novel obesity  treatment approach that seems destined for failure from EnteroMedics (NASDAQ: ETRM  )

Will anyone win the war on obesity?
With EnteroMedics seemingly out of the picture, can VIVUS pick up its lagging sales, or will Arena Pharmaceuticals reign supreme in the obesity space? If you're in the dark, grab copies of The Motley Fool's premium research reports on VIVUS and Arena Pharmaceuticals to stay up to date. Senior biotech analyst Brian Orelli gives investors the must-know information, including an in-depth look at the obesity market and reasons to buy and sell both stocks. Click now for an exclusive look at Arena and VIVUS -- complete with a full year of free updates -- today.


Read/Post Comments (2) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 08, 2013, at 1:45 PM, SamFreedom wrote:

    Brenton,

    You just proved yourself to be a hack w less talent than a jr high school kid writing a book report.

    For example, what investors did you speak with to determine this alleged doubt w ARNA due to Qysmia's lackluster performance. How many of them said, "You know, Brenton, because Qysmia's marketing sucked and it's REMS are a huge millstone around it's neck, and because the EMA rejected it, I'm having doubts about the SAFER Belviq that has the rock star sales force ready to roll it out.

    That makes no sense.

    Let me explain why there might be doubt....

    Because careless amateur hacks like you plus ppl who seen to have personal vendettas, like Adam Feuerstein, continually post negative, worrisome, doubtful news around ARNA wo giving much attention to its unique circumstances - circumstances with which many bright ppl have painstakingly replied in rebuttal articles and in comment sections.

    You should be more careful. This isn't monopoly money. To many ill-informed "authors" simply use ARNA as a springboard for their egomaniacal desire to get article views and, in my opinion, you just did it.

    I mean what did you really tell us other than your belief that "investors" are cowards because VVUS performed like crap? Should I be scarred if you if your cousin makes an unforced idiotic error?

  • Report this Comment On February 08, 2013, at 2:06 PM, SamFreedom wrote:

    Here is an example of excellent analysis:

    mD0TseekingalphaD0Tcom/article/1167551

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2244818, ~/Articles/ArticleHandler.aspx, 8/21/2014 2:52:57 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement